ClinicalTrials.gg
CompletedNCT01445067Updated Mar 1, 2023

Study to Evaluate the PK of BMS-927711 in Patient With Migraine During Acute Migraine and Non-migraine Condition

A Phase 1 interventional study of BMS-927711 (CGRP Antagonist) and BMS-927711 (CGRP Antagonist) in Migraine, sponsored by Pfizer. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-01.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing rimegepant in Migraine Disorders — 13 open to participants now, 15 under way, 6 of them phase 3. rimegepant · Migraine Disorders.

Enrollment
31st of 32
48 · median 618
Started
2011
with 1 other
Phase 1
2 of 32
1 open now
Registered
2nd of 32
by date
Lead sponsor
24 of 32
Pfizer

Among the 32 studies testing rimegepant in Migraine Disorders, this one is the 31st largest by enrollment, is one of 2 that started in 2011, is one of 2 in phase 1, and was the 2nd registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

13 of the 32 studies testing rimegepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About rimegepant

rimegepant: first FDA approval 2020 (NURTEC ODT), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing rimegepant in Migraine Disorders, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the pharmacokinetics (PK) of BMS-927711 during migraine and non-migraine condition.

Read the detailed description

Study Classification: Safety CGRP = Calcitonin gene related peptide

03

Conditions studied

  • Migraine

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with migraine with or without aura who are otherwise healthy as determined by medical history, physical examination, clinical laboratory evaluations and 12-lead (ECG), will be eligible
  • Men or women [women of (WOCBP) or Women of non childbearing potential (WONCBP)] ages 18-55 years inclusive, with a (BMI) of 18.0 to 32.0 kg/m2 with not more than 8 migraines a month
  • Patient has at least 1 year history of migraines (with or without aura) including the following:

    1. Meet the diagnostic criteria for migraine with history of at least 1 year (with or without aura) at the screening visit
    2. Migraine attacks with the age of onset prior to 55 years old
    3. Migraine attacks, on average, lasts about 4-72 hours if untreated in the 3 months prior to screening visit
  • 2-8 moderate or severe migraine attacks per month in the 3 months prior to screening visit. The migraine, for which the patient receives treatment during the study, must have at least one of the associated symptoms: nausea, photophobia, phonophobia, or migraine with aura

Exclusion criteria

Exclusion Criteria:

  • Female patient is pregnant/breast-feeding (or is a female expecting to conceive during study period)
  • Patient has history or evidence of stroke/, heart disease, coronary artery vasospasm, other significant underlying cardiovascular diseases, uncontrolled hypertension (high blood pressure), uncontrolled diabetes, or (HIV)
  • Patient will be excluded if they take medications for acute migraine more than 10 days per month, had very frequent chronic tension type headaches for 15 or more days per month (or were unable to distinguish between tension-type headaches and migraine)
  • Patient has major depression, other pain syndromes that might interfere with study assessments, psychiatric conditions, dementia, or significant neurological disorders (other than migraine)
  • Patient has a history of gastric, or small intestinal surgery, or has a disease that causes mal absorption
  • Patient has a history or current evidence of any unstable medical conditions (eg, history of congenital heart disease or arrhythmia, known suspected infection, or C, or cancer) that, in the investigator's opinion, would expose them to undue risk of a significant adverse event (AE) or interfere with assessments of safety or efficacy during the course of the trial
  • Patient has basilar migraine and hemiplegic migraine
  • Patient taking narcotic medication
  • History of alcohol, substance or drug abuse within the last year
  • Uses an opiate as acute treatment for migraine attacks
  • History of ergotamine, any acute therapy or triptan intake on greater than/equal 10 days per month on a regular basis for greater than/equal 3 months
  • History of simple analgesic intake on greater than/equal 10 days per month for greater than/equal 3 months
  • History of use of opioid or combination medication intake or butalbital containing analgesic greater than 5 days per month for greater than/equal to 3 months
  • Do not receive migraine relief from a triptan migraine treatment
  • Evidence of renal impairment - calculated \<60ml/min or finding on urinalysis
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Active comparator
    Arm 1: BMS-927711 (300 mg)

    Drug: BMS-927711 (CGRP Antagonist)

  • Active comparator
    Arm 2: BMS-927711 (600 mg)

    Drug: BMS-927711 (CGRP Antagonist)

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax) of BMS-927711 will be derived from plasma concentration versus time

    Time frame: PK samples will be collected for up to 24 hours after the dosing

  2. Time of maximum observed plasma concentration (Tmax) of BMS-927711 will be derived from plasma concentration versus time

    Time frame: PK samples will be collected for up to 24 hours after the dosing

  3. Area under the plasma concentration-time curve from time zero to 24 hours post dose [AUC(0-24)] of BMS-927711 will be derived from plasma concentration versus time

    Time frame: PK samples will be collected for up to 24 hours after the dosing

  4. Observed plasma concentration at 0.5 hr (C0.5h) of BMS-927711 will be derived from plasma concentration versus time

    Time frame: PK samples will be collected for up to 24 hours after the dosing

  5. Observed plasma concentration at 2h (C2h) of BMS-927711 will be derived from plasma concentration versus time

    Time frame: PK samples will be collected for up to 24 hours after the dosing

  6. Apparent total body clearance (CLT/F) of BMS-927711 will be derived from plasma concentration versus time

    Time frame: PK samples will be collected for up to 24 hours after the dosing

Secondary outcomes

  1. Maximum observed plasma concentration (Cmax) will be derived from plasma concentration versus time

    Individual subject pharmacokinetic parameter values will be derived by non compartmental methods by a validated pharmacokinetic program. Actual times will be used for the analyses

    Time frame: From Day 1 0 hour to Day 2 24 hour time points

  2. Time of maximum observed plasma concentration (Tmax) will be derived from plasma concentration versus time

    Individual subject pharmacokinetic parameter values will be derived by non compartmental methods by a validated pharmacokinetic program. Actual times will be used for the analyses

    Time frame: From Day 1 0 hour to Day 2 24 hour time points

  3. Area under the plasma concentration-time curve from time zero to 24 hours post dose [AUC (0-24)] will be derived from plasma concentration versus time

    Individual subject pharmacokinetic parameter values will be derived by non compartmental methods by a validated pharmacokinetic program. Actual times will be used for the analyses

    Time frame: From Day 1 0 hour to Day 2 24 hour time points

  4. Observed plasma concentration at 0.5 hr (C0.5h) will be derived from plasma concentration versus time

    Individual subject pharmacokinetic parameter values will be derived by non compartmental methods by a validated pharmacokinetic program. Actual times will be used for the analyses

    Time frame: From Day 1 0 hour to Day 2 24 hour time points

  5. Observed plasma concentration at 2 hr (C2h) will be derived from plasma concentration versus time

    Individual subject pharmacokinetic parameter values will be derived by non compartmental methods by a validated pharmacokinetic program. Actual times will be used for the analyses

    Time frame: From Day 1 0 hour to Day 2 24 hour time points

  6. Apparent total body clearance (CLT/F) will be derived from plasma concentration versus time

    Individual subject pharmacokinetic parameter values will be derived by non compartmental methods by a validated pharmacokinetic program. Actual times will be used for the analyses

    Time frame: From Day 1 0 hour to Day 2 24 hour time points

07

Study locations

4 sites
  • California Clinical Trials Medical Group
    Glendale, California 91206, United States
  • Collaborative Neuroscience Network, Inc.
    Long Beach, California 90806, United States
  • Compass Research, Llc
    Orlando, Florida 32806, United States
  • Community Research
    Cincinnati, Ohio 45255, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2011
First posted
Oct 3, 2011
Start
Nov 2011
Primary completionActual
Sep 2012
CompletionActual
Sep 2012
Last update
Mar 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01445067
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 3, 2011
Start date
Nov 2011
Primary completion
Sep 2012
Completion
Sep 2012
Last update
Mar 1, 2023

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimegepant

Start the discussion